Clinical Trial Update: Special Drug Use-results Surveillance of Tafinlar/Mekinist

View source ↗

Summary

Clinical-trial update reporting ongoing surveillance of the dabrafenib/trametinib combination (Tafinlar/Mekinist) for BRAF V600E mutation-positive unresectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Braf V600e-mutant Cancer
• Solid Tumors

Drugs mentioned

• MEKINIST (trametinib)
• TAFINLAR (DABRAFENIB)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor | Status: RECRUITING